Engineering poly(lactic-co-glycolic acid) (PLGA) micro- and nano-carriers for Controlled Delivery of 17β-Estradiol

Alesia V. Prakapenka, Heather Bimonte-Nelson, Rachael W. Sirianni

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


With menopause, circulating levels of 17β-estradiol (E2) markedly decrease. E2-based hormone therapy is prescribed to alleviate symptoms associated with menopause. E2 is also recognized for its beneficial effects in the central nervous system (CNS), such as enhanced cognitive function following abrupt hormonal loss associated with ovariectomy. For women with an intact uterus, an opposing progestogen component is required to decrease the risk of developing endometrial hyperplasia. While adding an opposing progestogen attenuates these detrimental effects on the uterus, it can attenuate the beneficial effects of E2 in the CNS. Poly(lactic-co-glycolic acid) (PLGA) micro- and nano- carriers (MNCs) have been heavily investigated for their ability to enhance the therapeutic activity of hydrophobic agents following exogenous administration, including E2. Multiple PLGA MNC formulation parameters, such as composition, molecular weight, and type of solvent used, can be altered to systematically manipulate the pharmacokinetic and pharmacodynamic profiles of encapsulated agents. Thus, there is an opportunity to enhance the therapeutic activity of E2 in the CNS through controlled delivery from PLGA MNCs. The aim of this review is to consider the fate of exogenously administered E2 and discuss how PLGA MNCs and route of administration can be used as strategies for controlled E2 delivery.

Original languageEnglish (US)
Pages (from-to)1697-1709
Number of pages13
JournalAnnals of Biomedical Engineering
Issue number7
StatePublished - Jul 1 2017


  • 17β-Estradiol
  • Cognition
  • Drug delivery
  • E2
  • Microparticle
  • Nanoparticle
  • PLGA
  • Polymer

ASJC Scopus subject areas

  • Biomedical Engineering


Dive into the research topics of 'Engineering poly(lactic-co-glycolic acid) (PLGA) micro- and nano-carriers for Controlled Delivery of 17β-Estradiol'. Together they form a unique fingerprint.

Cite this